公开(公告)号：US20240197685A1

公开(公告)日：2024-06-20

申请号：US18283484

申请日：2022-03-23

Applicant: Vicore Pharma AB

Inventor： Tomas Fex ,  Bengt Ohlsson ,  Anders Hallberg ,  Mats Larhed

IPC: A61K31/4178 ,  A61K31/4439 ,  C07D409/10 ,  C07D409/14

CPC classification number: A61K31/4178 ,  A61K31/4439 ,  C07D409/10 ,  C07D409/14

Abstract: There is provided pharmaceutical compounds of formula (I), wherein R1, R2, R3, R4, R5, R6, Y1, Y2, Y3 and Y4 have meanings given in the description, which compounds are useful in the treatment of autoimmune and/or fibrotic diseases, including interstitial lung diseases, such as idiopathic pulmonary fibrosis and sarcoidosis.

公开(公告)号：US20230159467A1

公开(公告)日：2023-05-25

申请号：US17912284

申请日：2021-03-18

Applicant: Vicore Pharma AB

Inventor： Anders Hallberg ,  Mats Larhed

IPC: C07D233/64 ,  C07D417/10 ,  C07D409/10 ,  C07D417/14 ,  C07D417/04 ,  C07D413/10

CPC classification number: C07D233/64 ,  C07D417/10 ,  C07D409/10 ,  C07D417/14 ,  C07D417/04 ,  C07D413/10

Abstract: The present disclosure relates to compounds of Formula (I) and to their utility in the treatment in a disease, disorder and/or condition associated with the peptide angiotensin II.

公开(公告)号：US20240182461A1

公开(公告)日：2024-06-06

申请号：US18283489

申请日：2022-03-23

Applicant: Vicore Pharma AB

Inventor： Tomas Fex ,  Bengt Ohlsson ,  Anders Hallberg ,  Mats Larhed

IPC: C07D417/14 ,  C07D233/58 ,  C07D401/12 ,  C07D409/12

CPC classification number: C07D417/14 ,  C07D233/58 ,  C07D401/12 ,  C07D409/12

Abstract: There is provided pharmaceutical compounds of formula I, wherein R1, R2, R3, R4, R6, X, Y, Z, Y1, Y2, Y3 and Y4 have meanings given in the description, which compounds are useful in the treatment of autoimmune and/or fibrotic diseases, including interstitial lung diseases, such as idiopathic pulmonary fibrosis and sarcoidosis.